TY  - BOOK
AU  - Ahmed Adel Mohamed Alaa Eldin
AU  - Ahmed Abdelbary Abdelrahman , 
AU  - Mina Ibrahim Tadros , 
TI  - A pharmaceutical study on certain modified release etodolac dosage forms / 
PY  - 2010///
CY  - Cairo : 
PB  - Ahmed Adel Mohamed Alaa Eldin , 
KW  - Controlled porosity osmotic pump ( CPOP ) tablets
KW  - Controlled release lipid matrix tablets
KW  - Etodolac
N1  - Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics; Issued also as CD
N2  - Etodolac is non - steroidal anti - inflammatory drug acting by a preferential inhibition of cyclo - oxygenase - 2 ( COX - 2 ) enzyme . It is used for rheumatoid arthritis , including juvenile idiopathic arthritis , osteoathritis and for the treatment of acute pain . It has an elimination half - life of 7 hour and the recommended oral dose , 200 to 400 mg, is given every 6 to 8 hours to a maximum of 1.2 g daily , therefore it is a potential cadidate for controlled release formulations
UR  - http://172.23.153.220/th.pdf
ER  -